Patients approach two years of complete HIV viral load suppression in phase 2b study
CytoDyn announced that the first of 11 HIV-1 patients receiving PRO 140 as a monotherapy in a Phase 2b extension study has reached two years of complete virologic suppression. Four additional patients are expected to reach the two-year benchmark in the next three weeks. August 23, 2016